Clinical Approaches to Ileal Pouch Dysfunction
Information source: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Pouchitis
Intervention: Electronic Barostat (Procedure)
Phase: Phase 3
Status: Completed
Sponsored by: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Official(s) and/or principal investigator(s):
Bo Shen, M.D., Principal Investigator, Affiliation: The Cleveland Clinic
Summary
Total proctocolectomy and ileal pouch-anal anastomosis is the surgical treatment of choice
for patients with medically refractory ulcerative colitis, ulcerative colitis with dysplasia
or cancer, and patients with familial adenomatous polyposis. Pouchitis, an inflammatory
process of the ileal pouch, is the most common long-term complication. Increased stool
frequency, abdominal pain, and pelvic discomfort are suggestive of pouchitis, approximately
40% of patients with these symptoms have no or minimal inflammation of the pouch or rectal
cuff on endoscopy and histopathology. These patients have a condition resembling irritable
bowel syndrome (IBS), which we termed the irritable pouch syndrome (IPS). The RATIONALE and
FEASIBILITY for the proposed study are: 1) IPS occurs in a substantial number of patients
with IPAA, significantly affecting the quality of life. However, IPS is rare in the general
population, and is considered an orphan disease. Studies such as those we propose can only be
conducted in centers with a large number of patients with IPAA. The Cleveland Clinic has
maintained the world's largest ileal pouch registry, with a total of more the 2,500 patients;
2) a series of investigations on the diagnosis and treatment of patients with inflammatory or
functional diseases of IPS, notably the initial study of IPS, have been conducted by our
team; 3) In contrast to IBS, the pathophysiology and treatment of IPS have not been studied.
Our HYPOTHESES are that 1) similar to IBS, visceral hypersensitivity may play a role in the
pathogenesis of IPS, and 2) amitriptyline, a safe and effective agent for patients with IBS,
will be more effective than placebo in alleviating symptoms and improving quality of life in
patients with IPS. The AIMS of the study are to 1) investigate visceral hypersensitivity
using barostat examination of the pouch; 2) conduct a randomized, placebo-controlled clinical
trial evaluating the use of amitriptyline in IPS.
Clinical Details
Study design: Treatment, Non-Randomized, Double-Blind, Placebo Control, Single Group Assignment, Safety/Efficacy Study
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:(must meet ALL of the following criteria);
- Having a history of UC and more than 1 year from TPC/IPAA
- Meet diagnostic criteria of IPS, i. e.
- Symptoms of diarrhea and abdominal pain, with PDAI symptoms score > (range 2-6).
- Duration of symptoms > 12 weeks in the preceding 12-months period
- Pouch endoscopy shows no evidence of inflammation of the ileal pouch and rectal cuff
- No antibiotic therapy, aspirin, or non-steriodal anti-inflammatory drugs for 2 weeks
prior to entry into the study; no antidepressant and or anti-anxiety medicines for at
least 4 weeks.
Exclusion Criteria:(may meet ANY of the following criteria);
- A history of development of side effects from amitriptyline
- IPAA for FAP; celiac disease; chronic pouchitis; Crohn's disease; pouch stricture or
anastomotic leak
- Urinary retention, glaucoma, use of MAO inhibitors within past 14 days; acute recovery
phase following myocardial infarction; pregnancy
- Psychiatric disorder, including major depression, which requires medical therapy
Locations and Contacts
Cleveland Clinic Foundation, Cleveland, Ohio 44195, United States
Additional Information
Ending date: December 2007
Last updated: February 19, 2008
|
